BioSig (BSGM) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 09, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		28,313,748
Amendment Flag	false
Entity Central Index Key	1,530,766
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 234,285	$ 1,055,895
Prepaid expenses	150,482	134,263
Total current assets	384,767	1,190,158
Property and equipment, net	18,866	24,188
Other assets:
Deposits	19,473	27,612
Total assets	423,106	1,241,958
Current liabilities:
Accounts payable and accrued expenses, including $10,990 and $15,755 to related parties as of June 30, 2017 and December 31, 2016, respectively	1,301,603	373,103
Dividends payable	396,939	359,891
Warrant liability	2,240,510	1,937,234
Derivative liability	285,032	288,934
Total current liabilities	4,224,084	2,959,162
Series C Preferred Stock, 1,005 and 1,070 shares issued and outstanding; liquidation preference of $1,005,000 and $1,070,000 as of June 30, 2017 and December 31, 2016, respectively	985,000	1,070,000
Stockholders' deficit
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B and 4,200 shares of Series C Preferred Stock	0	0
Common stock, $0.001 par value, authorized 200,000,000 shares, 25,627,565 and 22,588,184 issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	26,414	22,588
Additional paid in capital	46,888,447	41,019,251
Common stock subscription	279,940	0
Accumulated deficit	(51,980,779)	(43,829,043)
Total stockholders’ deficit	(4,785,978)	(2,787,204)
Total liabilities and stockholders’ deficit	$ 423,106	$ 1,241,958

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Accounts payable and accrued expenses, related parties (in Dollars)	$ 17,888	$ 15,755
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	26,413,745	22,588,184
Common stock, shares outstanding	26,413,745	22,588,184
Series C Preferred Stock [Member]
Preferred stock, shares issued	985	1,070
Preferred stock, shares outstanding	985	1,070
Preferred stock, liquidation preference (in Dollars)	$ 985,000	$ 1,070,000
Preferred stock, shares authorized	4,200	4,200
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Operating expenses:
Research and development	$ 1,124,506	$ 560,514	$ 3,802,149	$ 2,139,671
General and administrative	786,948	991,852	4,020,625	7,257,852
Depreciation	2,834	2,570	8,900	7,811
Total operating expenses	1,914,288	1,554,936	7,831,674	9,405,334
Loss from operations	(1,914,288)	(1,554,936)	(7,831,674)	(9,405,334)
Other income (expense):
Gain (loss) on change in fair value of derivatives	113,724	17,771	(320,131)	(807,087)
Interest income	15	0	69	1
Loss before income taxes	(1,800,549)	(1,537,165)	(8,151,736)	(10,212,420)
Income taxes (benefit)	0	0	0	0
Net loss	(1,800,549)	(1,537,165)	(8,151,736)	(10,212,420)
Preferred stock dividend	(22,307)	(24,726)	(68,915)	(85,467)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (1,822,856)	$ (1,561,891)	$ (8,220,651)	$ (10,297,887)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.07)	$ (0.08)	$ (0.33)	$ (0.55)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	26,071,408	20,581,041	24,762,649	18,847,515

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 9 months ended Sep. 30, 2017 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Subscription [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2016	$ 22,588	$ 41,019,251		$ (43,829,043)	$ (2,787,204)
Balance (in Shares) at Dec. 31, 2016	22,588,184				22,588,184
Sale of common stock	$ 2,871	4,118,033			$ 4,120,904
Sale of common stock (in Shares)	2,870,865
Common stock issued for services	$ 625	894,124			$ 894,749
Common stock issued for services (in Shares)	625,000				625,000
Common stock issued upon conversion of Series C Preferred Stock at $1.50 per share	$ 57	84,943			$ 85,000
Common stock issued upon conversion of Series C Preferred Stock at $1.50 per share (in Shares)	56,669				135,000
Common stock issued settlement of Series C Preferred Stock accrued dividends at $1.37 per share	$ 24	31,844			$ 31,868
Common stock issued settlement of Series C Preferred Stock accrued dividends at $1.37 per share (in Shares)	24,021
Common stock received and canceled in connection with short term swing profit reimbursement	$ (11)	11
Common stock received and canceled in connection with short term swing profit reimbursement (in Shares)	(10,744)
Common stock subscription received			$ 279,940		279,940
Reclassify fair value of derivative liability to equity upon conversion of Series C Preferred Stock to common shares		20,757			20,757
Fair value of warrant issued to acquire research and development		543,927			543,927
Stock based compensation	$ 260	244,472			244,732
Stock based compensation (in Shares)	259,750
Preferred Stock dividend		(68,915)			(68,915)
Net loss				(8,151,736)	(8,151,736)
Balance at Sep. 30, 2017	$ 26,414	$ 46,888,447	$ 279,940	$ (51,980,779)	$ (4,785,978)
Balance (in Shares) at Sep. 30, 2017	26,413,745				26,413,745

CONDENSED STATEMENT OF STOCKHO6

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)	9 Months Ended
	Sep. 30, 2017$ / shares
Common stock issued upon conversion, per share	$ 1.50
Common stock issued settlement of Series C Preferred Stock accrued dividends, per share	$ 1.37

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (8,151,736)	$ (10,212,420)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	8,900	7,811
Equipment distribution as officer compensation	3,210	0
Change in derivative liabilities	320,131	807,087
Equity based compensation	1,139,481	5,453,240
Fair value of issued warrant to acquire research and development	543,927	0
Changes in operating assets and liabilities:
Prepaid expenses	(16,219)	(103,222)
Security deposit	8,139	0
Accounts payable	930,110	202,534
Deferred rent payable	(1,609)	417
Net cash used in operating activities	(5,215,666)	(3,844,553)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(6,788)	(12,095)
Net cash used in investing activity	(6,788)	(12,095)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	4,120,904	3,053,868
Proceeds from common stock subscription	279,940	0
Net cash provided by financing activities	4,400,844	3,053,868
Net increase in cash and cash equivalents	(821,610)	(802,780)
Cash and cash equivalents, beginning of the period	1,055,895	953,234
Cash and cash equivalents, end of the period	234,285	150,454
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	0	0
Cash paid during the period for income taxes	0	0
Non cash investing and financing activities:
Reclassify derivative liability to equity	20,757	97,897
Series C Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	$ 116,868	$ 465,355

NOTE 1 - NATURE OF OPERATIONS A

NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2017
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The condensed balance sheet as of December 31, 2016 has been derived from audited financial statements. Operating results for the three and nine months ended September 30, 2017 are not necessarily indicative of results that may be expected for the year ending December 31, 2017. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2016 filed with the Company’s Form 10-K with the Securities and Exchange Commission on March 30, 2017.

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of September 30, 2017, the Company had cash of $234,285 and working capital deficit (current liabilities in excess of current assets) of $3,839,317 principally due to the inclusion of non-cash derivative and warrant liabilities recorded in current liabilities. In addition, the Company raised approximately $4,401,000 in nine months ended September 30, 2017 through the sale of common stock and warrants and approximately $2,850,000 subsequent to September 30, 2017 (See Note 12). As of September 30, 2017, excluding the derivative and warrant liabilities, the Company’s working capital deficit would have been $1,313,775. During the nine months ended September 30, 2017, the Company used net cash in operating activities of $5,215,666. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 4 months. The Company’s primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders’ deficiencies at September 30, 2017 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed financial statements do not include any adjustment that might result from the outcome of this uncertainty.

NOTE 3 - SUMMARY OF SIGNIFICANT

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2017 and December 31, 2016, the Company did not have any derivative instruments that were designated as hedges. At September 30, 2017 and December 31, 2016, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 7). Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1,124,506 and $3,802,149 for the three and nine months ended September 30, 2017; and $560,514 and $2,139,671 for the three and nine months ended September 30, 2016, respectively. Net Earnings (Loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of September 30, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2017 September 30, 2016 Series C convertible preferred stock 656,667 726,667 Options to purchase common stock 6,829,421 8,090,190 Warrants to purchase common stock 11,380,582 8,333,235 Totals 18,866,670 17,150,092 Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. As of September 30, 2017, the Company had 6,829,421 options outstanding to purchase shares of common stock, of which 6,427,005 were vested. As of December 31, 2016, the Company had 8,245,190 options outstanding to purchase shares of common stock, of which 7,028,639 were vested. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. Registration Rights The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations. Beginning on October 28, 2016, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company anticipates early adoption of this pronouncement effective January 1, 2018. As such, the impact would the reclassification of the December 31, 2017 fair values of our warrant and derivative liabilities to equity. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed financial statements, except as disclosed.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment as of September 30, 2017 and December 31, 2016 is summarized as follows: September 30, 2017 December 31, 2016 Computer equipment $ 85,549 $ 84,704 Furniture and fixtures 11,837 10,117 Subtotal 97,386 94,821 Less accumulated depreciation (78,520 ) (70,633 ) Property and equipment, net $ 18,866 $ 24,188 During the nine months ended September 30, 2017, the Company distributed equipment with a book value of $3,210 to a prior employee in connection with a settlement agreement. Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Depreciation expense was $2,834 and $8,900 for the three and nine months ended September 30, 2017, respectively; and $2,570 and $7,811 for the three and nine months ended September 30, 2016, respectively.

NOTE 5 - ACCOUNTS PAYABLE AND A

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at September 30, 2017 and December 31, 2016 consist of the following: September 30, 2017 December 31, 2016 Accrued accounting and legal $ 165,424 $ 120,464 Accrued reimbursements 12,222 43,116 Accrued consulting 23,481 1,192 Accrued research and development expenses 1,083,848 181,884 Accrued office and other 1,992 10,202 Deferred rent 1,303 2,912 Accrued settlement related to arbitration 13,333 13,333 $ 1,301,603 $ 373,103

NOTE 6 - SERIES C 9% CONVERTIBL

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK	9 Months Ended
	Sep. 30, 2017
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 6 – SERIES C 9% CONVERTIBLE PREFERRED STOCK On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including: ● incur additional indebtedness; ● permit liens on assets; ● repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock; ● pay cash dividends to our stockholders; and ● engage in transactions with affiliates. Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection. In the event that: (i) we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered, (ii) we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered, (iii) we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv) we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered, (v) we are party to a change of control transaction, (vi) we file for bankruptcy or a similar arrangement or are adjudicated insolvent, (vii) we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days, The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%. The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C Preferred Stock outside of equity. In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date. The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301. In accordance with ASC 470-20, at issuance, the Company recognized an embedded beneficial conversion feature present in the Series C Preferred Stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital. The aggregate debt discount, comprised of the relative intrinsic value of the conversion option ($1,303,671), the relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590), for a total of $2,781,000, is amortized over an estimated one year as interest expense. During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C Preferred Stock. During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C Preferred Stock for net proceeds of $1,814,910. At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required. There was no established market for the Company’s common stock. As described in Note 7, as of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities. At March 31, 2015, the Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: contractual terms of 2.78 to 3.50 years, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141.00%. During January 2015, the Company issued an aggregate of 42,334 shares of its common stock in exchange for 50 shares of the Company’s Series C Preferred Stock and accrued dividends. During March 2015, the Company issued an aggregate of 169,334 shares of its common stock in exchange for 200 shares of the Company’s Series C Preferred Stock and accrued dividends. In April 2015, the Company issued an aggregate of 152,401 shares of its common stock in exchange for 180 shares of the Company’s Series C Preferred Stock and accrued dividends. On May 11, 2015, the Company sold an aggregate of 450 shares of its Series C Preferred Stock for net proceeds of $450,000. In connection with the sale, the Company issued 374,641 warrants to purchase the Company’s common stock at an exercise price of $1.50 per share for five years with certain reset provisions as described above. The Company determined the initial fair values of the embedded beneficial conversion feature of the Series C Preferred Stock and the reset provisions of the related issued warrants $506,348 and $334,784, respectively, using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.25%, a dividend yield of 0%, and volatility of 140.00%. The determined fair values were recorded as liabilities and a charge to current period operations. In May 2015, the Company issued an aggregate of 273,473 shares of its common stock in exchange for 323 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2015, the Company issued an aggregate of 296,333 shares of its common stock in exchange for 350 shares of the Company’s Series C Preferred Stock and accrued dividends. In July 2015, the Company issued an aggregate of 169,333 shares of its common stock in exchange for 200 shares of the Company’s Series C Preferred Stock and accrued dividends. In October 2015, the Company issued an aggregate of 143,935 shares of its common stock in exchange for 170 shares of the Company’s Series C Preferred Stock and accrued dividends. In November 2015, the Company issued an aggregate of 99,061 shares of its common stock in exchange for 117 shares of the Company’s Series C Preferred Stock and accrued dividends. In December 2015, the Company issued an aggregate of 84,667 shares of its common stock in exchange for 100 shares of the Company’s Series C Preferred Stock and accrued dividends. In February 2016, the Company issued an aggregate of 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends. In May 2016, the Company issued an aggregate of 197,713 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends. In December 2016, the Company issued an aggregate of 18,188 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2017, the Company issued an aggregate of 60,846 shares of its common stock in exchange for 65 shares of the Company’s Series C Preferred Stock and accrued dividends. In July 2017, the Company issued an aggregate of 19,844 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends. Series C Preferred Stock issued and outstanding totaled 985 and 1,070 as of September 30, 2017 and December 31, 2016, respectively. As of September 30, 2017 and December 31, 2016, the Company has accrued $396,939 and $359,891 dividends payable on the Series C Preferred Stock. Registration Rights Agreement In connection with the Company’s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount. Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events. The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014 and has subsequently filed required registration statements to maintain effectiveness.

NOTE 7 - WARRANT AND DERIVATIVE

NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES	9 Months Ended
	Sep. 30, 2017
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 7 – WARRANT AND DERIVATIVE LIABILITIES At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required. There was no established market for the Company’s common stock. As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively. The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89, a dividend yield of 0%, and volatility of 141.00%. At September 30, 2017, the Company marked to market the fair value of the reset provisions of the Series C Preferred Stock and warrants and determined fair values of $285,032 and $2,240,510, respectively. The Company recorded a gain (loss) from change in fair value of derivatives of $113,724 and $(320,131) for the three and nine months ended September 30, 2017, respectively, and $17,771 and $(807,087) for the three and nine months ended September 30, 2016, respectively. The fair values of the embedded derivatives as of September 30, 2017 were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 0.25 to 2.61 years, a risk free interest rate of 1.05% to 1.47%, a dividend yield of 0%, and volatility of 150%.

NOTE 8 - STOCKHOLDER EQUITY

NOTE 8 - STOCKHOLDER EQUITY	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 – STOCKHOLDER EQUITY Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of September 30, 2017 and December 31, 2016, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock and 4,200 shares of Series C Preferred Stock. As of September 30, 2017 and December 31, 2016, there were 0 and 0 Series A and Series B preferred stock outstanding and 985 and 1,070 outstanding shares of Series C preferred stock, respectively. In June 2017, the Company issued 60,846 shares of its common stock in exchange for 65 shares of the Company’s Series C Preferred Stock and accrued dividends. In July 2017, the Company issued an aggregate of 19,844 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends. Common stock The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of September 30, 2017 and December 31, 2016, the Company had 26,413,745 and 22,588,184 shares issued and outstanding, respectively. During the nine months ended September 30, 2017, the Company issued an aggregate of 625,000 shares of its common stock for services totaling $894,749 ($1.43 per share). During the nine months ended September 30, 2017, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,870,865 shares of common stock and 1,615,964 warrants for aggregate proceeds of $4,120,904, net of $185,394 in expenses. During the nine months ended September 30, 2017, the Company issued an aggregate of 135,000 and 124,750 shares of its common stock for vested restricted stock units and stock based compensation previously accrued in 2016. In April 2017, the Company received and canceled 10,744 shares of its common stock as payment for short-swing profit pursuant to Section 16(b) of the U.S. Securities Exchange Act of 1934, as amended from an officer and member of the Company’s Board of Directors.

NOTE 9 - OPTIONS, RESTRICTED ST

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS	9 Months Ended
	Sep. 30, 2017
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Options On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 15,186,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith. Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The following table presents information related to stock options at September 30, 2017: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 2,144,642 5.9 1,742,226 2.01-3.00 4,384,779 3.9 4,384,779 3.01-4.00 300,000 7.5 300,000 6,829,421 4.7 6,427,005 A summary of the stock option activity and related information for the 2012 Plan for the nine months ended September 30, 2017 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2016 8,245,190 $ 2.24 5.8 $ - Grants - 0 $ - Exercised - Canceled (1,415,769 ) 2.17 Outstanding at September 30, 2017 6,829,421 $ 2.26 4.7 $ 2,000 Exercisable at September 30, 2017 6,427,005 $ 2.29 4.6 $ 1,363 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.36 as of September 30, 2017, which would have been received by the option holders had those option holders exercised their options as of that date. Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of stock-based payment awards during the nine months ended September 30, 2017 and 2016 was estimated using the Black-Scholes pricing model. The fair value of all options vesting during the three and nine months ended September 30, 2017 of $54,243 and $151,470, respectively and during the three and nine months ended September 30, 2016 of $218,085 and $2,512,886, respectively, was charged to current period operations. Unrecognized compensation expense of $135,041 and $310,817 at September 30, 2017 and December 31, 2016, respectively, will be expensed in future periods. Restricted Stock The following table summarizes the restricted stock activity for the nine month ended September 30, 2017: Total restricted shares issued as of December 31, 2016 135,000 Granted - Vested (135,000 ) Vested restricted shares as of September 30, 2017 - Unvested restricted shares as of September 30, 2017 - Stock based compensation expense related to restricted stock grants was $2,380 and $93,262 for the three and nine months ended September 30, 2017; $70,753 and $124,139 for the three and nine months ended September 30, 2016. As of September 30, 2017, the stock-based compensation relating to restricted stock of $0 remains unamortized. Warrants The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2017: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 7,258,936 February 2018 to September2020 $ 1.84 35,076 January 2020 $ 1.95 1,689,026 October 2018 to September 2019 $ 2.00 100,000 August 2018 $ 2.02 30,755 January 2020 $ 2.50 100,000 August 2018 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 11,380,582 On February 9, 2017, the Company exchanged 38,572 warrants with an exercise price of $2.10 with 45,001 warrants with an exercise price of $1.50, all other terms and conditions the same, to 2016 investors to adjust offered terms in connection with the Company’s equity raise with other investors. On February 10, 2017, the Company issued an aggregate of 300,628 warrants to purchase the Company’s common stock at $1.50 per share, expiring on February 10, 2020, in connection with the sale of the Company’s common stock. On March 10, 2017, the Company issued an aggregate of 197,159 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 10, 2020, in connection with the sale of the Company’s common stock. On March 15, 2017, the Company issued 630,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 15, 2020, to Mayo Foundation in connection with a know-how licensing agreement (See Note 10). The fair value of the of the issued warrants of $543,927, determined using the Black-Scholes option model with an estimated volatility of 105.22%, risk free rate of 1.599%, dividend yield of -0- and fair value of the Company’s common stock of $1.37, was charged to current period operations as acquired research and development. On March 31, 2017, the Company issued an aggregate of 157,250 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 31, 2020, in connection with the sale of the Company’s common stock. On April 6, 2017, the Company issued an aggregate of 288,300 warrants to purchase the Company’s common stock at $1.50 per share, expiring on April 6, 2020, in connection with the sale of the Company’s common stock. On May 5, 2017, the Company issued an aggregate of 6,667 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 5, 2020, in connection with the sale of the Company’s common stock. On May 17, 2017, the Company issued an aggregate of 186,957 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 17, 2020, for placement agent services in connection with the sale of the Company’s common stock. On June 20, 2017, the Company issued 10,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on June 20, 2020, in connection with the sale of the Company’s common stock. On June 30, 2017, the Company issued an aggregate of 108,334 warrants to purchase the Company’s common stock at $1.50 per share, expiring on June 30, 2020, in connection with the sale of the Company’s common stock. On July 13, 2017, the Company issued an aggregate of 133,501 warrants to purchase the Company’s common stock at $1.50 per share, expiring on July 13, 2020, in connection with the sale of the Company’s common stock. On August 18, 2017, the Company issued an aggregate of 175,500 warrants to purchase the Company’s common stock at $1.50 per share, expiring on August 18, 2020, in connection with the sale of the Company’s common stock. On September 18, 2017, the Company issued an aggregate of 51,668 warrants to purchase the Company’s common stock at $1.50 per share, expiring on September 18, 2020, in connection with the sale of the Company’s common stock. Stock based compensation related to warrants issued for services was $0 for the three and nine months ended September 30, 2017 and $641 and $56,930 for the three and nine months ended September 30, 2016, respectively. A summary of the warrant activity for the nine months ended September 30, 2017 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2016 9,128,189 $ 1.96 2.1 $ 494,099 Grants 2,290,965 $ 1.50 3.0 - Exercised - Canceled (38,572 ) $ 2.10 2.4 - Outstanding at September 30, 2017 11,380,582 $ 1.87 1.8 $ 563,097 Vested and expected to vest at September 30, 2017 11,380,582 $ 1.86 1.6 $ 520,932 Exercisable at September 30, 2017 11,380,582 $ 1.86 1.6 $ 520,932 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $1.36 as of September 30, 2017, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.

NOTE 10 - COMMITMENTS AND CONTI

NOTE 10 - COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 10 – COMMITMENTS AND CONTINGENCIES On March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale. The agreement expires in ten years from the effective date. The Company is obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined. In consideration, the Company issued 630,000 warrants to acquire the Company’s common stock at an exercise price of $1.50, expiring on March 15, 2020.

NOTE 11 - FAIR VALUE MEASUREMEN

NOTE 11 - FAIR VALUE MEASUREMENT	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 11 – FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity. As of September 30, 2017 and December 31, 2016, the Company did not have any items that would be classified as level 1 or 2 disclosures. The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 7. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 5 are that of volatility and market price of the underlying common stock of the Company. As of September 30, 2017 and December 31, 2016, the Company did not have any derivative instruments that were designated as hedges. The derivative and warrant liability as of September 30, 2017, in the amount of $285,032 and $2,240,510, respectively, has a level 3 classification. The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of September 30, 2017: Warrant Liability Derivative Balance, December 31, 2016 $ 1,937,234 $ 288,934 Total (gains) losses Transfers out due to conversion of Series C Preferred Stock - (20,757 ) Mark to market to September 30, 2017 303,276 16,855 Balance, September 30, 2017 $ 2,240,510 $ 285,032 Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2017 $ (303,276 ) $ (16,855 ) Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

NOTE 12 - SUBSEQUENT EVENTS

NOTE 12 - SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 12 – SUBSEQUENT EVENTS Series D Preferred stock On November 3, 2017, the Company filed the Certificate of Designations for the Series D Preferred Stock with the Secretary of State of the State of Delaware. Pursuant to such Certificate of Designations, in the event of the Company’s liquidation or winding up of its affairs, the holders of Preferred Shares will be entitled to a liquidation preference of the stated value per Preferred Share of $1,500 (the “Stated Value”) plus any accrued but unpaid dividends or any other fees due the holder. A total of 1,400 shares were designated as Series D Preferred Stock. A holder of Preferred Shares is entitled at any time to convert any whole or partial number of shares of Preferred Shares into shares of Common Stock determined by dividing the Stated Value of the Preferred Shares being converted by the conversion price of $1.50 per share (the “Conversion Price”). The Conversion Price is subject to “full ratchet” anti-dilution price protection upon the issuance of equity or equity-linked securities at a price lower than the Conversion Price as well as other customary anti-dilution protection. A holder of the Preferred Shares shall be entitled to receive cumulative dividends at the rate per Preferred Share (as a percentage of the Stated Value per Preferred Share) of 9% per annum, with respect to the Series D Preferred Stock on each date that such Holder converts Preferred Shares into common stock (with respect only to Preferred Shares being converted). The Company may pay such dividends, at its option, in cash, common stock or a combination thereof. Payment of dividends in shares of common stock is subject to the satisfaction of certain equity conditions set forth in the Certificate of Designations. Upon the conversion of Preferred Shares prior to November 3, 2020, the Company shall also pay to the Holders of the Preferred Shares so converted cash, or at the Company’s option, common stock or a combination thereof, with respect to the Preferred Shares so converted in an amount equal to $270 per $1,000 of Stated Value of the Preferred Shares being converted, less the amount of all prior dividends paid on such converted Preferred Shares before the relevant date of conversion. Preferred stock On November 3, 2017, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,334 shares (the “Preferred Shares”) of its Series D Preferred Stock, par value $0.001 per share, and Class A Warrants to purchase an aggregate of 667,000 shares of the Company’s common stock, par value $0.001 per share at an exercise price of $1.75 per share (the “Class A Warrants”), in exchange for aggregate net cash proceeds of $1,929,975, net of expenses of $70,025. Contemporaneously with the entry into the Purchase Agreement, the Company and the Purchasers agreed to exchange outstanding warrants to purchase 780,506 shares of the Common Stock at an exercise price of $1.50 per share for new Class B Warrants to purchase an equal number of shares of common stock at the same exercise price (the “Class B Warrants”). The Purchase Agreement contains representations and warranties of the Company and the Investors that are typical for transactions of this type. The Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type, as well as a prohibition on the Company’s ability to enter into equity line financings or other variable rate transactions. In connection with the entry into the Purchase Agreement, the Investors and the Company also entered into a registration rights agreement whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 45 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Class A Warrants and Class B Warrants (the “Warrants”), (c) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Warrants, and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered. The Company will use its reasonable best efforts to cause such registration statement to be declared effective by the SEC (such date, the “Effectiveness Date”) within 90 days of the Filing Date. If (i) the registration statement is not filed on or prior to the Filing Date, (ii) the Company fails to file with the SEC a request for acceleration of a registration statement within 5 calendar days of the date that the Company is notified by the SEC that such registration statement will not be reviewed or will not be subject to further review, (iii) prior to the effective date of a registration statement, the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the SEC in respect of such registration statement within 30 days after the receipt of comments by or notice from the SEC that such amendment is required in order for such registration statement to be declared effective, (iv) the registration statement is not declared effective by the Effectiveness Date or (v) certain other events described in the registration rights agreement (each, an “Event”), then the Company shall pay liquidated damages to the Investors in an amount equal to 1% of the aggregate purchase price paid by the Investors on the day of delinquency and each 30th day of delinquency thereafter. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the Registration Rights Agreement shall be 10% of the aggregate purchase price paid by the Investors. Class A Warrants are exercisable immediately and expire on May 3, 2021, and have an exercise price of $1.75 per share. The Class B Warrants are exercisable immediately and expire on November 3, 2020, and have an exercise price of $1.50. The Class A Warrants and Class B Warrants otherwise have similar terms, including, a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock at a per share price lower than the applicable exercise price then in effect. Common stock On October 11, 2017, the Company entered into securities purchase agreements with investors, pursuant to which the Company received from subscriptions for the purchase of 386,667 shares of the Company’s common stock and warrants to purchase 193,334 shares of our common stock at $1.50, expiring three years from issuance, for aggregate net cash proceeds of $579,760, net of expenses of $140 (of which $279,940 were received as common stock subscriptions as of September 30, 2017). The shares of common stock were issued on October 11, 2017. On October 25, 2017, the company granted awards to key employees, key consultants, and outside directors of 1,100,000 shares of restricted common stock; and incentive options to purchase 675,000 shares of common stock with a date of grant that is ten trading days following the date hereof and an exercise price equal to the arithmetic mean of the market price for such common stock for the ten trading days immediately preceding the grant date. On November 6, 2017, the Company entered into securities purchase agreements with investors, pursuant to which the Company received from subscriptions for the purchase of 413,336 shares of the Company’s common stock and warrants to purchase 200,001 shares of our common stock at $1.50, expiring three years from issuance, for aggregate net cash proceeds of $619,830, net of expenses of $171.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2017 and December 31, 2016, the Company did not have any derivative instruments that were designated as hedges. At September 30, 2017 and December 31, 2016, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 7).
Research and Development Expense, Policy [Policy Text Block]	Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1,124,506 and $3,802,149 for the three and nine months ended September 30, 2017; and $560,514 and $2,139,671 for the three and nine months ended September 30, 2016, respectively.
Earnings Per Share, Policy [Policy Text Block]	Net Earnings (Loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of September 30, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2017 September 30, 2016 Series C convertible preferred stock 656,667 726,667 Options to purchase common stock 6,829,421 8,090,190 Warrants to purchase common stock 11,380,582 8,333,235 Totals 18,866,670 17,150,092
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. As of September 30, 2017, the Company had 6,829,421 options outstanding to purchase shares of common stock, of which 6,427,005 were vested. As of December 31, 2016, the Company had 8,245,190 options outstanding to purchase shares of common stock, of which 7,028,639 were vested.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Registration Rights Policy [Policy Text Block]	Registration Rights The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations. Beginning on October 28, 2016, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company anticipates early adoption of this pronouncement effective January 1, 2018. As such, the impact would the reclassification of the December 31, 2017 fair values of our warrant and derivative liabilities to equity. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed financial statements, except as disclosed.

NOTE 3 - SUMMARY OF SIGNIFICA21

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2017 September 30, 2016 Series C convertible preferred stock 656,667 726,667 Options to purchase common stock 6,829,421 8,090,190 Warrants to purchase common stock 11,380,582 8,333,235 Totals 18,866,670 17,150,092

NOTE 4 - PROPERTY AND EQUIPME22

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of September 30, 2017 and December 31, 2016 is summarized as follows: September 30, 2017 December 31, 2016 Computer equipment $ 85,549 $ 84,704 Furniture and fixtures 11,837 10,117 Subtotal 97,386 94,821 Less accumulated depreciation (78,520 ) (70,633 ) Property and equipment, net $ 18,866 $ 24,188

NOTE 5 - ACCOUNTS PAYABLE AND23

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2017
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at September 30, 2017 and December 31, 2016 consist of the following: September 30, 2017 December 31, 2016 Accrued accounting and legal $ 165,424 $ 120,464 Accrued reimbursements 12,222 43,116 Accrued consulting 23,481 1,192 Accrued research and development expenses 1,083,848 181,884 Accrued office and other 1,992 10,202 Deferred rent 1,303 2,912 Accrued settlement related to arbitration 13,333 13,333 $ 1,301,603 $ 373,103

NOTE 9 - OPTIONS, RESTRICTED 24

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure Text Block Supplement [Abstract]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at September 30, 2017: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 2,144,642 5.9 1,742,226 2.01-3.00 4,384,779 3.9 4,384,779 3.01-4.00 300,000 7.5 300,000 6,829,421 4.7 6,427,005
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity and related information for the 2012 Plan for the nine months ended September 30, 2017 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2016 8,245,190 $ 2.24 5.8 $ - Grants - 0 $ - Exercised - Canceled (1,415,769 ) 2.17 Outstanding at September 30, 2017 6,829,421 $ 2.26 4.7 $ 2,000 Exercisable at September 30, 2017 6,427,005 $ 2.29 4.6 $ 1,363
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock activity for the nine month ended September 30, 2017: Total restricted shares issued as of December 31, 2016 135,000 Granted - Vested (135,000 ) Vested restricted shares as of September 30, 2017 - Unvested restricted shares as of September 30, 2017 -
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2017: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 7,258,936 February 2018 to September2020 $ 1.84 35,076 January 2020 $ 1.95 1,689,026 October 2018 to September 2019 $ 2.00 100,000 August 2018 $ 2.02 30,755 January 2020 $ 2.50 100,000 August 2018 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 11,380,582
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the nine months ended September 30, 2017 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2016 9,128,189 $ 1.96 2.1 $ 494,099 Grants 2,290,965 $ 1.50 3.0 - Exercised - Canceled (38,572 ) $ 2.10 2.4 - Outstanding at September 30, 2017 11,380,582 $ 1.87 1.8 $ 563,097 Vested and expected to vest at September 30, 2017 11,380,582 $ 1.86 1.6 $ 520,932 Exercisable at September 30, 2017 11,380,582 $ 1.86 1.6 $ 520,932

NOTE 11 - FAIR VALUE MEASUREM25

NOTE 11 - FAIR VALUE MEASUREMENT (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of September 30, 2017: Warrant Liability Derivative Balance, December 31, 2016 $ 1,937,234 $ 288,934 Total (gains) losses Transfers out due to conversion of Series C Preferred Stock - (20,757 ) Mark to market to September 30, 2017 303,276 16,855 Balance, September 30, 2017 $ 2,240,510 $ 285,032 Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2017 $ (303,276 ) $ (16,855 )

NOTE 2 - GOING CONCERN AND MA26

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	Nov. 03, 2017	Nov. 09, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]
Cash and Cash Equivalents, at Carrying Value			$ 234,285	$ 150,454	$ 1,055,895	$ 953,234
Working Capital (Deficit)			(3,839,317)
Net Cash Provided by (Used in) Financing Activities			4,400,844	3,053,868
Proceeds from Issuance or Sale of Equity			279,940	0
Net Cash Provided by (Used in) Operating Activities			(5,215,666)	$ (3,844,553)
Working Capital, Excluding Derivative and Warrant Liabilities [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]
Working Capital (Deficit)			$ (1,313,775)
Subsequent Event [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]
Proceeds from Issuance or Sale of Equity	$ 1,929,975	$ 2,850,000

NOTE 3 - SUMMARY OF SIGNIFICA27

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Accounting Policies [Abstract]
Research and Development Expense	$ 1,124,506	$ 560,514	$ 3,802,149	$ 2,139,671
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,829,421		6,829,421		8,245,190
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	6,427,005		6,427,005		7,028,639

NOTE 3 - SUMMARY OF SIGNIFICA28

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	18,866,670	17,150,092
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	656,667	726,667
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	6,829,421	8,090,190
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	11,380,582	8,333,235

NOTE 4 - PROPERTY AND EQUIPME29

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Gain (Loss) on Disposition of Property Plant Equipment			$ 3,210
Depreciation	$ 2,834	$ 2,570	$ 8,900	$ 7,811
Minimum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life			5 years

NOTE 4 - PROPERTY AND EQUIPME30

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 97,386	$ 94,821
Less accumulated depreciation	(78,520)	(70,633)
Property and equipment, net	18,866	24,188
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	85,549	84,704
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 11,837	$ 10,117

NOTE 5 - ACCOUNTS PAYABLE AND31

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$ 165,424	$ 120,464
Accrued reimbursements	12,222	43,116
Accrued consulting	23,481	1,192
Accrued research and development expenses	1,083,848	181,884
Accrued office and other	1,992	10,202
Deferred rent	1,303	2,912
Accrued settlement related to arbitration	13,333	13,333
	$ 1,301,603	$ 373,103

NOTE 6 - SERIES C 9% CONVERTI32

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)	Mar. 15, 2017	May 11, 2015	Feb. 06, 2013	Jan. 09, 2013	Jul. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	May 31, 2016	Feb. 29, 2016	Dec. 31, 2015	Nov. 30, 2015	Oct. 31, 2015	Jul. 31, 2015	Jun. 30, 2015	May 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Mar. 31, 2015	Jul. 31, 2013	Sep. 30, 2017	Dec. 31, 2013	Dec. 31, 2013
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Rights, Granted		374,641		1,330,627																		2,290,965
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 1.50		$ 2.61
Warrants, Term of Warrants		5 years		5 years
Warrant, Description of Warrant				after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.
Class of Warrant or Right, Outstanding							9,128,189															11,380,582
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars)																						$ 543,927
Temporary Equity, Amortization Period																							1 year
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)		$ 506,348					$ 288,934											$ 1,242,590		$ 1,242,590		285,032
Fair Value Assumptions, Risk Free Interest Rate	1.599%
Fair Value Assumptions, Expected Dividend Rate	0.00%																			0.00%
Fair Value Assumptions, Expected Volatility Rate	105.22%																			141.00%
Conversion of Stock, Shares Issued					19,844	60,846	18,188	54,759	197,713	54,859	84,667	99,061	143,935	169,333	296,333	273,473	152,401	169,334	42,334
Derivative Liability, Current (in Dollars)		$ 334,784					$ 1,937,234											$ 4,097,444		$ 4,097,444		2,240,510
Dividends Payable, Current (in Dollars)							359,891															$ 396,939
Registration Payment Arrangement, Term																						the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.
Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Shares Authorized				4,200
Preferred Stock, Dividend Rate, Percentage				9.00%
Temporary Equity, Par Value (in Dollars)				$ 1,000
Preferred Stock, Dividend Payment Terms				payable quarterly
Preferred Stock, Voting Rights				The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.
Preferred Stock, Beneficial Ownership Limitation and Covenant, Description				The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:●incur additional indebtedness;●permit liens on assets;●repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;●pay cash dividends to our stockholders; and●engage in transactions with affiliates.
Convertible Preferred Stock, Terms of Conversion				Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.In the event that:(i) we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,(ii) we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,(iii) we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv) we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,(v) we are party to a change of control transaction,(vi) we file for bankruptcy or a similar arrangement or are adjudicated insolvent, (vii) we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.
Temporary Equity, Redemption Price Per Share (in Dollars per share)				$ 1.50
Temporary Equity, Liquidation Preference (in Dollars)							$ 1,070,000															$ 985,000	$ 2,781,000	$ 2,781,000
Stock Issued During Period, Shares, New Issues		450																			2,181
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)																					$ 1,814,910
Conversion of Stock, Shares Converted					20	65	20	70	236	75	100	117	170	200	350	323	180	200
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)		$ 450,000
Temporary Equity, Shares Outstanding							1,070															985
Temporary Equity, Shares Issued							1,070															985
Full-Ratchet Anti-Dilution Protection Provision [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 1.50
Class of Warrant or Right, Outstanding				2,315,301
Minimum [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term																				2 years 284 days
Fair Value Assumptions, Risk Free Interest Rate																				0.56%
Maximum [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term																				3 years 6 months
Fair Value Assumptions, Risk Free Interest Rate																				0.89%
Options Held [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other (in Dollars)																								1,303,671
Temporary Equity, Liquidation Preference (in Dollars)																							1,303,671	1,303,671
Warrant [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)																		$ 4,097,444		$ 4,097,444
Warrant [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars)																								1,064,739
Temporary Equity, Liquidation Preference (in Dollars)																							1,064,739	1,064,739
Issuance Costs [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Liquidation Preference (in Dollars)																							$ 412,590	$ 412,590
Embedded Derivative Financial Instruments [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term		2 years
Fair Value Assumptions, Risk Free Interest Rate		0.25%
Fair Value Assumptions, Expected Dividend Rate		0.00%																				0.00%
Fair Value Assumptions, Expected Volatility Rate		140.00%																				150.00%
Embedded Derivative Financial Instruments [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Conversion of Stock, Shares Converted																			50
Embedded Derivative Financial Instruments [Member] | Minimum [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term																						3 months
Fair Value Assumptions, Risk Free Interest Rate																				0.56%		1.05%
Embedded Derivative Financial Instruments [Member] | Maximum [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term																						2 years 222 days
Fair Value Assumptions, Risk Free Interest Rate																				0.89%		1.47%
Bridge Loan [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			600

NOTE 7 - WARRANT AND DERIVATI33

NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) - USD ($)	Mar. 15, 2017	May 11, 2015	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability		$ 506,348	$ 285,032		$ 1,242,590	$ 285,032		$ 288,934
Derivative Liability, Current		$ 334,784	2,240,510		$ 4,097,444	2,240,510		$ 1,937,234
Fair Value Assumptions, Risk Free Interest Rate	1.599%
Fair Value Assumptions, Expected Dividend Rate	0.00%				0.00%
Fair Value Assumptions, Expected Volatility Rate	105.22%				141.00%
Derivative, Gain (Loss) on Derivative, Net			$ 113,724	$ 17,771		$ (320,131)	$ (807,087)
Minimum [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate					0.56%
Fair Value Assumptions, Expected Term					2 years 284 days
Maximum [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate					0.89%
Fair Value Assumptions, Expected Term					3 years 6 months
Embedded Derivative Financial Instruments [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		0.25%
Fair Value Assumptions, Expected Dividend Rate		0.00%				0.00%
Fair Value Assumptions, Expected Volatility Rate		140.00%				150.00%
Fair Value Assumptions, Expected Term		2 years
Embedded Derivative Financial Instruments [Member] | Minimum [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate					0.56%	1.05%
Fair Value Assumptions, Expected Term						3 months
Embedded Derivative Financial Instruments [Member] | Maximum [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate					0.89%	1.47%
Fair Value Assumptions, Expected Term						2 years 222 days

NOTE 8 - STOCKHOLDER EQUITY (De

NOTE 8 - STOCKHOLDER EQUITY (Details) - USD ($)	May 11, 2015	Jan. 09, 2013	Jul. 31, 2017	Jun. 30, 2017	Apr. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	May 31, 2016	Feb. 29, 2016	Dec. 31, 2015	Nov. 30, 2015	Oct. 31, 2015	Jul. 31, 2015	Jun. 30, 2015	May 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Jul. 31, 2013	Sep. 30, 2017	Sep. 30, 2016
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized						1,000,000														1,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)						$ 0.001														$ 0.001
Conversion of Stock, Shares Issued			19,844	60,846		18,188	54,759	197,713	54,859	84,667	99,061	143,935	169,333	296,333	273,473	152,401	169,334	42,334
Common Stock, Shares Authorized						200,000,000														200,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)						$ 0.001														$ 0.001
Common Stock, Shares, Outstanding						22,588,184														26,413,745
Common Stock, Shares, Issued						22,588,184														26,413,745
Stock Issued During Period, Shares, Issued for Services																				625,000
Stock Issued During Period, Value, Issued for Services (in Dollars)																				$ 894,749
Sale of Stock, Price Per Share (in Dollars per share)																				$ 1.43
Class of Warrant or Rights, Granted	374,641	1,330,627																		2,290,965
Proceeds from Issuance or Sale of Equity (in Dollars)																				$ 279,940	$ 0
Stock Issued During Period, Shares, Conversion of Convertible Securities																				135,000
Stock Issued During Period, Shares, Share-based Compensation, Gross																				124,750
Stock Repurchased and Retired During Period, Shares					10,744
Series A Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized						200														200
Preferred Stock, Shares Outstanding																				0
Series B Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized						600														600
Preferred Stock, Shares Outstanding																				0
Series C Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized						4,200														4,200
Preferred Stock, Shares Outstanding						1,070														985
Conversion of Stock, Shares Converted			20	65		20	70	236	75	100	117	170	200	350	323	180	200
Stock Issued During Period, Shares, New Issues	450																		2,181
Securities Purchase Agreements [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																				2,870,865
Class of Warrant or Rights, Granted																				1,615,964
Proceeds from Issuance or Sale of Equity (in Dollars)																				$ 4,120,904
Payments of Stock Issuance Costs (in Dollars)																				$ 185,394

NOTE 9 - OPTIONS, RESTRICTED 35

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - USD ($)	Sep. 18, 2017	Aug. 18, 2017	Jun. 30, 2017	Jun. 20, 2017	May 17, 2017	May 05, 2017	Apr. 06, 2017	Mar. 31, 2017	Mar. 15, 2017	Mar. 10, 2017	Feb. 10, 2017	Feb. 09, 2017	May 11, 2015	Jan. 09, 2013	Oct. 19, 2012	Jul. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share Price									$ 1.37								$ 1.36			$ 1.36
Share-based Compensation (in Dollars)																				$ 1,139,481	$ 5,453,240
Class of Warrant or Right, Exercise Price of Warrants or Rights													$ 1.50	$ 2.61
Class of Warrant or Rights, Granted (in Shares)													374,641	1,330,627						2,290,965
Fair Value Assumptions, Expected Volatility Rate									105.22%										141.00%
Fair Value Assumptions, Risk Free Interest Rate									1.599%
Fair Value Assumptions, Expected Dividend Rate									0.00%										0.00%
Warrant [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation (in Dollars)																	$ 0	$ 641		$ 0	56,930
Warrants at $2.10 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Warrants, Exchanged (in Shares)												38,572
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 2.10
Warrants at $1.50 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50					$ 1.50			$ 1.50
Class of Warrant or Rights, Granted (in Shares)	51,668	175,500	108,334	10,000	186,957	6,667	288,300	157,250	630,000	197,159	300,628	45,001
Warrant, Expriation Date	Sep. 18, 2020	Aug. 18, 2020	Jun. 30, 2020	Jun. 20, 2020	May 17, 2020	May 5, 2020	Apr. 6, 2020	Mar. 31, 2020	Mar. 15, 2020	Mar. 10, 2020	Feb. 10, 2020					Jul. 13, 2020
Warrants, Fair Value of Warrants, Granted (in Dollars)									$ 543,927
Warrants at $1.50 [Member] | Warrant [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																$ 1.50
Class of Warrant or Rights, Granted (in Shares)																133,501
Maximum [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate																			0.89%
Employee Stock Option [Member] | 2012 Equity Incentive Plan [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)															15,186,123
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award															the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.
Share Price																	$ 1.36			$ 1.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)																	$ 54,243	218,085		$ 151,470	2,512,886
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)																	135,041			135,041		$ 310,817
Employee Stock Option [Member] | Maximum [Member] | 2012 Equity Incentive Plan [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period															10 years
Restricted Stock Units (RSUs) [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation (in Dollars)																	2,380	$ 70,753		93,262	$ 124,139
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)																	$ 0			$ 0

NOTE 9 - OPTIONS, RESTRICTED 36

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	6,829,421	8,245,190
Options Outstanding, Weighted Average Remaining Life	4 years 255 days	5 years 292 days
Options Exercisable, Number of Options	6,427,005
Options at $1.01-$2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 1.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 2
Options Outstanding, Number of Options	2,144,642
Options Outstanding, Weighted Average Remaining Life	5 years 328 days
Options Exercisable, Number of Options	1,742,226
Options at $2.01-$3.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 2.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 3
Options Outstanding, Number of Options	4,384,779
Options Outstanding, Weighted Average Remaining Life	3 years 328 days
Options Exercisable, Number of Options	4,384,779
Options at $3.01-$4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 3.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 4
Options Outstanding, Number of Options	300,000
Options Outstanding, Weighted Average Remaining Life	7 years 6 months
Options Exercisable, Number of Options	300,000

NOTE 9 - OPTIONS, RESTRICTED 37

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares	6,829,421	8,245,190
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 2.26	$ 2.24
Options Outstanding, Weighted-Average Remaining Contractual Term	4 years 255 days	5 years 292 days
Options Outstanding, Aggregate Intrinsic Value (in Dollars)	$ 2,000	$ 0
Options Exercisable, Shares	6,427,005	7,028,639
Options Exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 2.29
Options Exercisable, Weighted-Average Remaining Contractual Term	4 years 219 days
Options Exercisable, Aggregate Intrinsic Value (in Dollars)	$ 1,363
Options Granted, Shares	0
Options Granted, Weighted-Average Remaining Contractual Term	0 years
Options Exercised, Shares	0
Options Exercised, Weighted-Average Exercise Price (in Dollars per share)	$ 0
Options Canceled, Shares	(1,415,769)
Options Canceled, Weighted-Average Exercise Price (in Dollars per share)	$ 2.17

NOTE 9 - OPTIONS, RESTRICTED 38

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2017shares
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]
Total restricted shares issued as of December 31, 2016	135,000
Granted	0
Vested	(135,000)
Vested restricted shares as of September 30, 2017	0
Unvested restricted shares as of September 30, 2017	0

NOTE 9 - OPTIONS, RESTRICTED 39

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares

9 Months Ended

Sep. 30, 2017

Sep. 18, 2017

Aug. 18, 2017

Jun. 30, 2017

Jun. 20, 2017

May 17, 2017

May 05, 2017

Apr. 06, 2017

Mar. 31, 2017

Mar. 15, 2017

Mar. 10, 2017

Feb. 10, 2017

Feb. 09, 2017

Dec. 31, 2016

May 11, 2015

Jan. 09, 2013

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 1.50

$ 2.61

Number of Warrants Outstanding

11,380,582

9,128,189

Warrants at $0.001 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 0.001

Number of Warrants Outstanding

383,320

Expiration Date, Warrants

January 2,020

Warrants at $1.50 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

Number of Warrants Outstanding

7,258,936

Expiration Date, Warrants

February 2018 to September2020

Warrants at $1.84 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 1.84

Number of Warrants Outstanding

35,076

Expiration Date, Warrants

January 2,020

Warrants at $1.95 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 1.95

Number of Warrants Outstanding

1,689,026

Expiration Date, Warrants

October 2018 to September 2019

Warrants at $2.00 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 2

Number of Warrants Outstanding

100,000

Expiration Date, Warrants

August 2,018

Warrants at $2.02 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 2.02

Number of Warrants Outstanding

30,755

Expiration Date, Warrants

January 2,020

Warrants at $2.50 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 2.50

Number of Warrants Outstanding

100,000

Expiration Date, Warrants

August 2,018

Warrants at $2.75 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 2.75

Number of Warrants Outstanding

228,720

Expiration Date, Warrants

August 2019 to September 2019

Warrants at $3.67 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 3.67

Number of Warrants Outstanding

214,193

Expiration Date, Warrants

December 2018 to January 2019

Warrants at $3.75 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 3.75

Number of Warrants Outstanding

1,340,556

Expiration Date, Warrants

April 2019 to March 2020

NOTE 9 - OPTIONS, RESTRICTED 40

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)	May 11, 2015	Jan. 09, 2013	Sep. 30, 2017	Dec. 31, 2016
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares			11,380,582	9,128,189
Warrants Outstanding, Weighted-Average Exercise Price			$ 1.87	$ 1.96
Warrants Outstanding, Weighted-Average Remaining Contractual Term			1 year 292 days	2 years 36 days
Warrants Outstanding, Aggregate Intrinsic Value			$ 563,097	$ 494,099
Warrants Vested and expected to vest, Shares			11,380,582
Warrants Vested and expected to vest, Weighted-Average Exercise Price			$ 1.86
Warrants Vested and expected to vest, Weighted-Average Remaining Contractual Term			1 year 219 days
Warrants Vested and expected to vest, Aggregate Intrinsic Value			$ 520,932
Warrants Exercisable, Shares			11,380,582
Warrants Exercisable, Weighted-Average Exercise Price			$ 1.86
Warrants Exercisable, Weighted-Average Remaining Contractual Term			1 year 219 days
Warrants Exercisable, Aggregate Intrinsic Value			$ 520,932
Warrants Granted, Shares	374,641	1,330,627	2,290,965
Warrants Granted, Weighted-Average Exercise Price			$ 1.50
Warrants Granted, Weighted-Average Remaining Contractual Term			3 years
Warrants Exercised, Shares			0
Warrants Exercised, Weighted-Average Exercise Price			$ 0
Warrants Canceled, Shares			(38,572)
Warrants Canceled, Weighted-Average Exercise Price			$ 2.10
Warrants Canceled, Weighted-Average Remaining Contractual Term			2 years 146 days

NOTE 10 - COMMITMENTS AND CON41

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) - $ / shares	Sep. 18, 2017	Aug. 18, 2017	Jun. 30, 2017	Jun. 20, 2017	May 17, 2017	May 05, 2017	Apr. 06, 2017	Mar. 31, 2017	Mar. 15, 2017	Mar. 10, 2017	Feb. 10, 2017	Feb. 09, 2017	May 11, 2015	Jan. 09, 2013	Jul. 31, 2017	Sep. 30, 2017
NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Agreement, Term									10 years
Class of Warrant or Rights, Granted (in Shares)													374,641	1,330,627		2,290,965
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)													$ 1.50	$ 2.61
Warrants at $1.50 [Member]
NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)	51,668	175,500	108,334	10,000	186,957	6,667	288,300	157,250	630,000	197,159	300,628	45,001
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50				$ 1.50
Warrant, Expriation Date	Sep. 18, 2020	Aug. 18, 2020	Jun. 30, 2020	Jun. 20, 2020	May 17, 2020	May 5, 2020	Apr. 6, 2020	Mar. 31, 2020	Mar. 15, 2020	Mar. 10, 2020	Feb. 10, 2020				Jul. 13, 2020
Minimum [Member]
NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Percentage of Net Sales									1.00%
Maximum [Member]
NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Percentage of Net Sales									2.00%

NOTE 11 - FAIR VALUE MEASUREM42

NOTE 11 - FAIR VALUE MEASUREMENT (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	May 11, 2015	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 285,032	$ 288,934	$ 506,348	$ 1,242,590
Derivative Liability, Current	$ 2,240,510	$ 1,937,234	$ 334,784	$ 4,097,444

NOTE 11 - FAIR VALUE MEASUREM43

NOTE 11 - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Loss on change in warrant and derivative liabilities for the year ended December 31, 2016	$ 113,724	$ 17,771	$ (320,131)	$ (807,087)
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance			1,937,234
Loss on change in warrant and derivative liabilities for the year ended December 31, 2016			(303,276)
Transfers out due to conversion of Series C Preferred Stock			0
Transfers out due to conversion of Series C Preferred Stock			0
Mark to market			303,276
Balance	2,240,510		2,240,510
Embedded Derivative Financial Instruments [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance			288,934
Loss on change in warrant and derivative liabilities for the year ended December 31, 2016			(16,855)
Transfers out due to conversion of Series C Preferred Stock			20,757
Transfers out due to conversion of Series C Preferred Stock			(20,757)
Mark to market			16,855
Balance	$ 285,032		$ 285,032

NOTE 12 - SUBSEQUENT EVENTS (De

NOTE 12 - SUBSEQUENT EVENTS (Details) - USD ($)	Nov. 06, 2017	Nov. 03, 2017	Oct. 25, 2017	Oct. 11, 2017	May 11, 2015	Jan. 09, 2013	Nov. 09, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Preferred Stock, Shares Authorized								1,000,000		1,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)								$ 0.001		$ 0.001
Class of Warrant or Rights, Granted					374,641	1,330,627		2,290,965
Common Stock, Par or Stated Value Per Share (in Dollars per share)								$ 0.001		$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					$ 1.50	$ 2.61
Proceeds from Issuance or Sale of Equity (in Dollars)								$ 279,940	$ 0
Warrants, Term of Warrants					5 years	5 years
Stock Issued During Period, Shares, Share-based Compensation, Gross								124,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								0
Securities Purchase Agreements [Member]
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues								2,870,865
Class of Warrant or Rights, Granted								1,615,964
Proceeds from Issuance or Sale of Equity (in Dollars)								$ 4,120,904
Payments of Stock Issuance Costs (in Dollars)								$ 185,394
Subsequent Event [Member]
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.001
Proceeds from Issuance or Sale of Equity (in Dollars)		$ 1,929,975					$ 2,850,000
Payments of Stock Issuance Costs (in Dollars)		$ 70,025
Subsequent Event [Member] | Series D Preferred Stock [Member]
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)		$ 1,500
Preferred Stock, Shares Authorized		1,400
Preferred Stock, Conversion Price (in Dollars per share)		$ 1.50
Preferred Stock, Dividend Rate, Percentage		9.00%
Convertible Preferred Stock, Terms of Conversion		Upon the conversion of Preferred Shares prior to November 3, 2020, the Company shall also pay to the Holders of the Preferred Shares so converted cash, or at the Company’s option, common stock or a combination thereof, with respect to the Preferred Shares so converted in an amount equal to $270 per $1,000 of Stated Value of the Preferred Shares being converted, less the amount of all prior dividends paid on such converted Preferred Shares before the relevant date of conversion.
Stock Issued During Period, Shares, New Issues		1,334
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.001
Subsequent Event [Member] | Sale of Class A Warrants [Member]
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Class of Warrant or Rights, Granted		667,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 1.75
Subsequent Event [Member] | Exchange of Outstanding Warrants for Class B Warrants [Member]
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Class of Warrant or Rights, Granted		780,506
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 1.50
Subsequent Event [Member] | Securities Purchase Agreements [Member]
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	413,336			386,667
Class of Warrant or Rights, Granted	200,001			193,334
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50			$ 1.50
Proceeds from Issuance or Sale of Equity (in Dollars)	$ 619,830			$ 579,760
Payments of Stock Issuance Costs (in Dollars)	$ 171			$ 140
Warrants, Term of Warrants	3 years			3 years
Stockholders' Equity Note, Subscriptions Receivable (in Dollars)				$ 279,940
Subsequent Event [Member] | Stock and Options Awarded to Key Employees, Consultants and Directors [Member]
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross			1,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			675,000